Home›Trial›NCT05967351
🔬NCT05967351Phase 3ENROLLING BY INVITATION

A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study

Study Summary

The purpose of this study is to provide a single clinical study with a uniform approach to monitoring long-term safety and efficacy in participants who received delandistrogene moxeparvovec in a previous clinical study. No study drug will be administered as part of this study.

Conditions
Duchenne Muscular Dystrophy
Interventions / Drugs
delandistrogene moxeparvovec
View on ClinicalTrials.gov ↗
Sponsor
SRPT
Sarepta Therapeutics
Gene Therapy
D44/100
Study Details
Enrollment400 participants
Primary Completion—
Lead SponsorSarepta Therapeutics, Inc.
Data Retrieved2026-04-11 02:55:56.327658+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.